Studies of a prophylactic HIV1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

Citation:
Barry S Peters, Walter Jaoko EVGPPFCSJG, Mampedi Bogoshi, Gloria Omosa-Manyonyi LDBFTTP-ABARC, Pieterse, Wendy Stevens RTBBAMMJMIGPTHJJA, bwayo. "Studies of a prophylactic HIV1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity." Vaccine. 2007;25(11):2120-7.

UoN Websites Search